NCT06926803View on ClinicalTrials.gov

A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Active, not recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

August 1, 2025

Conditions

Lung Cancer (NSCLC)Leptomeningeal Cancer

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Qiming Wang

OTHER_GOV